Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
April 1, 2025
After six months of anticoagulation maintenance, 2.5 mg BID dose of apixaban is not inferior to a full dose and showed less bleeding.
About This Site
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
